Boulder, CO, July 20, 2017 – Nivalis Therapeutics, Inc. (Nivalis) (Nasdaq:NVLS) announced today that, based upon the final vote count certified by the independent inspector of elections for the special...
Read More
Alpine Immune Sciences Announces Presentation of Preclinical Data Showing Potency of Its First-Generation Dual ICOS and CD28 Antagonist vIgDs in an Animal Model -- Company Plans to File IND in...
Read More
Nivalis Therapeutics, Inc. and Alpine Immune Sciences, Inc. Agree to Combine - Plan to Accelerate Development of Novel Immunotherapies Focused on Inflammation and Immuno-Oncology - - Combined Company Well Capitalized...
Read More
Alpine Immune Sciences Announces $48 Million Series A Financing to Support Discovery and Development of the Next Generation of Immunotherapies Company will leverage its proprietary vIgDTM platform using directed evolution...
Read More